3 results
8-K
EX-99.2
OLMA
Olema Pharmaceuticals, Inc.
15 May 24
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
7:06am
18 (36%) Chemotherapy 9 (18%) ESR1 mutations at baseline (ctDNA), n/N (%) 13/48* (27%) Palazestrant-Ribociclib DemographicsOf 50 patients, 70% had
8-K
EX-99.1
OLMA
Olema Pharmaceuticals, Inc.
8 Jan 24
Olema Oncology JP Morgan Conference January 2024
9:07am
formulation should reduce upper GI adverse events Demographics Safety: Well Tolerated Favorable Pharmacokinetics Abbreviations: CDK4/6i, cyclin dependent … Demographics Safety: Well tolerated Favorable Pharmacokinetics
Palazestrant Phase 1b/2 in Combination with Palbociclib Well tolerated with no DLTs
8-K
EX-99.2
OLMA
Olema Pharmaceuticals, Inc.
23 Oct 23
Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant
7:45am
enrolled Nov 2022
7 Patient Demographics and Baseline Characteristics Patients Received Extensive Prior Therapies Characteristics 120 mg palazestrant N
- Prev
- 1
- Next